Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole October 17, 2023
Sitryx Raises Additional $39 Million to Progress Development of Disease-modifying Therapeutics for Chronic AutoImmune and Inflammatory Disease September 27, 2023
Axial Therapeutics Announces Completion of Enrollment in Global Phase 2b Clinical Trial for AB-2004 for Irritability Associated with Autism September 26, 2023
Lassen Therapeutics Presents New Data on LASN01 for the Treatment of Idiopathic Pulmonary Fibrosis and Thyroid Eye Disease September 12, 2023
Solu Therapeutics Appoints Philip Vickers, Ph.D., as President and Chief Executive Officer September 11, 2023
XyloCor Therapeutics Presents Phase 2 Data Highlighting Safety and Efficacy of XC001 at the European Society of Cardiology (ESC) Congress 2023 September 6, 2023
